Home » CABP » Page 4

Tag Archives: CABP

AZD-0914: A New Broad-Spectrum Narrow-Development Path Drug

Posted on by — No Comments ↓

At first glance, the list of features that distinguish AZD-0914 from other FQ seems impressive: broad Gram-positive and Gram-negative activity, MRSA and MSSA activity, potency against fluoroquinolone (FQ)-resistant isolates, low frequency for S. aureus resistance, and impressive activity against C. difficile. In addition, researchers mention a peculiar MoA for this gyrase/topoisomerase Continue reading AZD-0914: A New Broad-Spectrum Narrow-Development Path Drug→

Solithromycin CAP Study:  Cap the Details (in the Publication)

Posted on by — No Comments ↓

In a recent publication, the results of a large Phase 3 trial comparing solithromycin with moxifloxacin in the treatment of CAP are presented [1]. As this was a global registration trial, we should refer to the indication as CABP, the current FDA acronym for a very defined entity which has some Continue reading Solithromycin CAP Study:  Cap the Details (in the Publication)→

QIDP Antibiotics – 2015 Year-End Update

Posted on by — No Comments ↓

Here an updated listing of all QIDP drugs we are aware of as of 12/24/2015. Today just facts and numbers; we will provide an interpretation of the current landscape in upcoming blogs. There are 58 drugs which garnered QIDP status and these are listed in the Main Table below. With the recent Continue reading QIDP Antibiotics – 2015 Year-End Update→